Cellestia is a spin-off from EPFL Lausanne developing targeted cancer therapies modulating the NOTCH signaling pathway. The lead compound is a first-in-class, oral pan-NOTCH inhibitor for treatment of NOTCH dependent cancer indications.

Cellestia Biotech AG
Technologiepark Basel
Hochbergerstrasse 60C
4057 Basel

Tel: +41 61 633 29 80


company website


testimonial about Technologiepark Basel

Cellestia Biotech AG is delighted about the opportunity to open our development office at Technologiepark Basel, which is a superb biotech incubator environment, working next door with other biotech companies and to share knowledge and expertise.